|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-6-21
|
|
pubmed:abstractText |
For pretargeting and other nuclear medicine applications, it may eventually be useful to radiolabel phosphodiamidate morpholinos (MORFs) with therapeutic radionuclides such as 188Re. However, by preparing 188Re-MORFs labelled conventionally with MAG3 as chelator, we have observed unacceptable levels of oxidation to perrhenate in vitro and in vivo in mice.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0143-3636
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
731-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15208502-Animals,
pubmed-meshheading:15208502-Drug Delivery Systems,
pubmed-meshheading:15208502-Drug Stability,
pubmed-meshheading:15208502-Isotope Labeling,
pubmed-meshheading:15208502-Male,
pubmed-meshheading:15208502-Metabolic Clearance Rate,
pubmed-meshheading:15208502-Mice,
pubmed-meshheading:15208502-Oligonucleotides,
pubmed-meshheading:15208502-Organ Specificity,
pubmed-meshheading:15208502-Oxidation-Reduction,
pubmed-meshheading:15208502-Radioisotopes,
pubmed-meshheading:15208502-Radiopharmaceuticals,
pubmed-meshheading:15208502-Rhenium,
pubmed-meshheading:15208502-Tissue Distribution
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Radiolabelling morpholinos with 188Re tricarbonyl provides improved in vitro and in vivo stability to re-oxidation.
|
|
pubmed:affiliation |
Division of Nuclear Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
